Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity

Autor: Otto C. Boerman, Erik Bennink, M H M G M den Brok, Roger P.M. Sutmuller, Gosse J. Adema, Liza W.J. Toonen, Theo J.M. Ruers, Cathelijne Frielink, Stefan Nierkens, Carl G. Figdor
Rok vydání: 2006
Předmět:
regulatory T cell
Cancer Research
dendritic cell
Regulatory T cell
medicine.medical_treatment
Aetiology
screening and detection [ONCOL 5]

Biology
Cancer Vaccines
Cryosurgery
Lymphocyte Depletion
Mice
Antigen
Antigens
Neoplasm

Immune Regulation [NCMLS 2]
Translational research [ONCOL 3]
In vivo
medicine
Animals
Antigen-presenting cell
Lymph node
Cell Differentiation
Immunotherapy
gene therapy and transplantation [UMCN 1.4]

Dendritic Cells
Neoplasms
Experimental

Immunotherapy
Dendritic cell
vaccination
Flow Cytometry
cryo ablation
Mice
Inbred C57BL

Pathogenesis and modulation of inflammation [N4i 1]
medicine.anatomical_structure
Oncology
CTLA-4
Immunology
Catheter Ablation
Cancer research
Female
radiofrequency ablation
Lymph Nodes
Microbial pathogenesis and host defense [UMCN 4.1]
Translational Therapeutics
Immunity
infection and tissue repair [NCMLS 1]
Zdroj: British Journal of Cancer, 95, 896-905
British Journal of Cancer, 95, 7, pp. 896-905
British Journal of Cancer
ISSN: 0007-0920
Popis: Contains fulltext : 49400.pdf (Publisher’s version ) (Closed access) Dendritic cells (DC) are professional antigen-presenting cells that play a pivotal role in the induction of immunity. Ex vivo-generated, tumour antigen-loaded mature DC are currently exploited as cancer vaccines in clinical studies. However, antigen loading and maturation of DC directly in vivo would greatly facilitate the application of DC-based vaccines. We formerly showed in murine models that radiofrequency-mediated tumour destruction can provide an antigen source for the in vivo induction of anti-tumour immunity, and we explored the role of DC herein. In this paper we evaluate radiofrequency and cryo ablation for their ability to provide an antigen source for DC and compare this with an ex vivo-loaded DC vaccine. The data obtained with model antigens demonstrate that upon tumour destruction by radiofrequency ablation, up to 7% of the total draining lymph node (LN) DC contained antigen, whereas only few DC from the conventional vaccine reached the LN. Interestingly, following cryo ablation the amount of antigen-loaded DC is almost doubled. Analysis of surface markers revealed that both destruction methods were able to induce DC maturation. Finally, we show that in situ tumour ablation can be efficiently combined with immune modulation by anti-CTLA-4 antibodies or regulatory T-cell depletion. These combination treatments protected mice from the outgrowth of tumour challenges, and led to in vivo enhancement of tumour-specific T-cell numbers, which produced more IFN-gamma upon activation. Therefore, in situ tumour destruction in combination with immune modulation creates a unique, 'in situ DC-vaccine' that is readily applicable in the clinic without prior knowledge of tumour antigens.
Databáze: OpenAIRE